Author | Scott Harris

September 07, 2016

Results unequivocally support early, aggressive, and sustained risk factor control in patients with complicated type 2 diabetes.

August 25, 2016

The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.